| Bioactivity | SARS-CoV-2 3CLpro-IN-7 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 value of 1.4 µM[1]. |
| Invitro | SARS-CoV-2 3CLpro-IN-7 (0-100 µM; 5, 30, 60, 180 min) 以剂量和时间依赖性方式抑制 SARS-CoV-2 3CLpro 活性 [1]。 |
| Name | SARS-CoV-2 3CLpro-IN-7 |
| CAS | 1164478-67-4 |
| Formula | C24H17ClN2O6 |
| Molar Mass | 464.85 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Wang L, et al. Discovery of novel SARS-CoV-2 3CL protease covalent inhibitors using deep learning-based screen. Eur J Med Chem. 2022 Dec 15;244:114803. |
SARS-CoV-2 3CLpro-IN-7
CAS: 1164478-67-4 F: C24H17ClN2O6 W: 464.85
SARS-CoV-2 3CLpro-IN-7 is a reversible covalent SARS-CoV-2 3CL protease inhibitor with an IC50 value of 1.4 µM.
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.